ID : CBI_3413 | Updated on : | Author : Yogesh K | Category : Medical Devices
Next Generation Sequencing Market size is estimated to reach over USD 48.08 Billion by 2035 from a value of USD 12.33 Billion in 2024 and is projected to grow by USD 13.95 Billion in 2025, growing at a CAGR of 13.17% from 2025 to 2035
Next generation sequencing can be defined as a high-throughput approach to analyze DNA and RNA sequences in a rapid manner. The next generation sequencing industry can be defined as the development and commercialization of next generation sequencing devices, reagents, sample preparation tools, bioinformatics tools, and data analysis tools. The main aim of next generation sequencing is to produce accurate genomic data in a shorter time and at a lower cost compared to other sequencing methods. The infrastructure supports clinical diagnostics, drug discovery, academic research, agricultural genomics, and population-scale sequencing programs.
The next generation sequencing sector is expanding due to the rising use of genomic testing in oncology and rare disease diagnosis. Healthcare institutions and research organizations are increasing investment in sequencing platforms and bioinformatics capabilities to support precision medicine initiatives. The development of large-scale genome initiatives and the integration of next generation sequencing in clinical practice are driving the next generation sequencing industry in hospitals, diagnostic centers, and research institutions.
AI improves next generation sequencing workflows by processing large volumes of genomic data, variant reads, and alignment outputs with high accuracy. Machine learning algorithms detect sequencing errors, low-quality reads, and variant inconsistencies across whole genome and targeted panels.
AI systems are also used for automated variant annotation, disease risk prediction, and pattern recognition within bioinformatics pipelines. Predictive models assess sequencing depth, sample quality, and data reliability before reporting, allowing laboratories to maintain diagnostic accuracy and reduce interpretation time across clinical and research applications.
The cancer cases are rising in developed and emerging countries worldwide, which is creating a need for molecular diagnostics. Hospitals and oncology centers are incorporating genomic profiling into routine cancer care to identify mutations and guide targeted therapy decisions. The comprehensive sequencing panels help clinicians understand cancer biology and develop personalized treatment strategies. Diagnostic laboratories are expanding sequencing capacity to manage rising oncology testing volumes.
Thus, the rising cancer cases worldwide are propelling the growth of next-generation sequencing services worldwide.
Huge investment is necessary for next generation sequencing instruments, associated hardware, as well as informatics tools. The setup of the laboratory involves further costs associated with data storage facilities, quality control equipment, as well as workforce recruitment. For small diagnostic centers, financial constraints are a hindrance for allocating budgets for next generation sequencing systems. Long payback periods on investment add financial risks to the healthcare market.
Therefore, a lot of capital investment is a major hindrance for the widespread adoption of next generation sequencing technologies by small and independent laboratories.
Liquid biopsy tests have started showing promise in oncology for cancer profiling and treatment monitoring. Blood-based tests for genomic analysis require highly sensitive targeted sequencing tests for the detection of mutations. Diagnostic companies are designing special tests that have shown promise for the analysis of DNA. The shift toward minimally invasive cancer diagnostics is expanding the use of sequencing in early detection and disease monitoring.
Thus, the expansion of liquid biopsy testing is creating new growth opportunities in the next generation sequencing market.
On the basis of offering, the next generation sequencing market is segmented into platform and consumables.
Trends in the Offering:
The consumables was responsible for the highest revenue share of 54.2% in 2024.
It is anticipated that the platforms will exhibit the highest compound annual growth rate (CAGR) during the forecast period.

On the basis of technology, the next generation sequencing market is segmented into WGS, whole exome sequencing, targeted sequencing and resequencing, and others.
Trends in the Technology:
The targeted sequencing and resequencing was responsible for the highest revenue share in 2024.
It is anticipated that the whole genome sequencing will exhibit the highest compound annual growth rate (CAGR) during the forecast period.
On the basis of workflow, the next generation sequencing market is segmented into pre-sequencing, sequencing, and NGS data analysis.
Trends in the Workflow:
The sequencing was responsible for the highest revenue share in 2024.
It is anticipated that the NGS data analysis will exhibit the highest compound annual growth rate (CAGR) during the forecast period.
On the basis of application, the next generation sequencing market is segmented into oncology, clinical investigation, reproductive health, HLA typing and immune system monitoring, metagenomics epidemiology and drug development, agrigenomics and forensics, and consumer genomics.
Trends in the Application:
The oncology was responsible for the highest revenue share in 2024.
It is anticipated that the reproductive health will exhibit the highest compound annual growth rate (CAGR) during the forecast period.
On the basis of end user, the next generation sequencing market is divided into academic and research institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users.
Trends in the End User:
Academic and Research institutes accounted for the largest revenue share in the year 2024.
Hospitals and clinics is anticipated to register the fastest CAGR during the forecast period.
North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America are the regions of coverage.

In 2024, North America accounted for the highest market share at 42.57% and was valued at USD 5.25 Billion, and is expected to reach USD 20.47 Billion by 2035. In North America, the U.S. accounted for the highest market share of 86.4% during the base year of 2024. This is driven by the strong adoption rate of genomic testing in cancer therapy and rare disease testing. The country has the presence of key players in the genetic sequencing technology space and established reimbursement systems. It is expanding its genome research initiatives through funding programs.

Asia Pacific market segment is expected to show the fastest growth during the forecast period. China is investing heavily in large-scale genome sequencing projects and developing domestic biotechnological capabilities. It is increasing the adoption of NGS technology for oncology diagnostics and prenatal screening in private hospitals in the country. Japan and South Korea are investing heavily in precision medicine initiatives by investing in national genomic initiatives. Rising healthcare expenditure is supporting installation of advanced sequencing platforms.
Europe next generation sequencing market growth is supported by government funded genome mapping programs in the UK, Germany, and France. Expansion of personalized medicine frameworks is increasing routine genomic profiling across public healthcare systems.
Latin America next generation sequencing market growth is supported by rising cancer testing volumes in Brazil and Mexico. Private diagnostic laboratories are increasingly using benchtop sequencers for expanding molecular testing services.
Middle East & Africa next generation sequencing market growth is supported by healthcare modernization programs in the UAE and Saudi Arabia. There is an increase in the use of genomic research in academic institutions in South Africa for infectious disease and population health research.
The next-generation sequencing market is moderately consolidated, with the presence of platform vendors, reagent vendors, and bioinformatics vendors. Firms are expanding their instrument offerings and data analysis capabilities. Associations with pharmaceutical companies and diagnostic laboratories are helping vendors establish themselves. The emphasis on automation continues to influence the competition. Key participants in the market for next generation sequencing include:
Product Launches
| Report Attributes | Report Details |
|---|---|
| Study Timeline | 2019-2035 |
| Market Size in 2035 (USD Billion) | USD 48.08 Billion |
| CAGR (2025-2035) | 13.17% |
| By Offering |
|
| By Technology |
|
| By Workflow |
|
| By Application |
|
| By End User |
|
| By Region |
|
| Key Players |
|
| Report Coverage |
|
The next generation sequencing market size is estimated to reach over USD 48.08 Billion by 2035 from a value of USD 12.33 Billion in 2024 and is projected to grow by USD 13.95 Billion in 2025, growing at a CAGR of 13.17% from 2025 to 2035.
The next generation sequencing report includes specific segmentation details for offering, technology, workflow, application, end user, and regions.
NGS data analysis is the fastest growing segment, driven by rising genomic data volumes and increasing adoption of AI-based bioinformatics tools.
The key participants in the next generation sequencing market are Illumina Inc. (US), Thermo Fisher Scientific Inc. (US), BGI Genomics Co. Ltd. (China), Agilent Technologies Inc. (US), Pacific Biosciences of California Inc. (US), Oxford Nanopore Technologies plc (UK), QIAGEN N.V. (Germany), Roche Sequencing Solutions Inc. (US), PerkinElmer Inc. (US), Eurofins Scientific SE (Luxembourg), and others.
The next generation sequencing market is shaped by expanding use of genomic profiling in oncology, growth in liquid biopsy testing, and integration of advanced bioinformatics platforms into clinical workflows.